ALFASIGMA

ALFASIGMA is a global pharmaceutical company and contract manufacturer based in Alanno, Italy, with a rich history spanning over 75 years, formed from the merger of Alfa Wassermann and Sigma-Tau. Established in 2015, the company employs between 2,001 and 5,000 people and reported a revenue of –1.87 billion in 2024. ALFASIGMA specializes in a broad range of pharmaceutical products, including Gastroenterology drugs for functional gastro-intestinal disorders, IBD, and chronic liver disease; Vascular disease treatments for venous diseases and diabetic microangiopathies; Rheumatology drugs; and Metabolic disease treatments focusing on Carnitine. Their product portfolio also extends to Nutraceuticals, Medical foods, and Self-medication products. The company operates a factory and provides comprehensive CDMO (Contract Development and Manufacturing Organization) services, including freeze-drying